Abstract:Background Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease with a poor prognosis in which synovitis induces progressive destruction of bones and joints, which leads to marked impairment of the activities of daily living.More timely and effective therapy for rheumatoid arthritis has contributed to increasing rates of clinical remission. However, progression of structural damage may still occur in patients who have satisfied remission criteria (1,2).Most RA patients who satisfied the remission criteria with normal findings on clinical and laboratory studies had imaging-detected synovitis may explain the observed discrepancy between disease activity and outcome in RA (3). Objectives To evaluate theeffects of double filtration plasmapheresis (DFPP) in combination with Leflunomide and methotrexate on magnetic resonance imaging (MRI)-detected inflammatory changes (synovitis and bone marrow edema) in early rheumatoid arthritis (RA) patients with high disease activity. Methods Sixty RA patients with high active disease of 6 months to3 years’ duration were randomized to DFPP group and no-DFPP group. All patients received leflunomide10mg, two times daily, plus methotrexate15mg orally once weekly. DFPP was performed in the DFPP group once 1-2 weeks for 3 sessions. The primary end point was the improvement in MRI-detected synovitis from baseline over 6 months. Secondary end point variables included Clinical remission in DAS28 and ACR20, ACR50, ACR70 and ACR90 responses for 6 consecutive months. Results The study achieved a significant reduction in synovitis compared with baseline, witha reduction of 7 in the median synovitis score from baseline to month 6in the DFPP group compared with 0 in the median synovitis score from baseline to month 6for the no-DFPP group (P<0.001). Synovitis scores in 48.39% (15/31)of the Patients in the DFPP group were 0 at month 6.Bone edema scores in 32.26% (10/31) of the Patients in the DFPP group were 0 at month 6. ACR20, ACR50, ACR70 and ACR90 responses for 6 consecutive months had been achieved in 100% of patients in the DFPP group, compared with 37.93%, 20.69%, 10.34%, 0% respectively, of patients in the no-DFPP group (P<0.001). DAS28 remissionfor 6 consecutive months was achieved in 100% of patients in the DFPP group, compared with 6.90%of patients in the no-DFPP group (P<0.001). Conclusions The combination of DFPP and DMARDs is superior to DMARDs alone for reducing MRI-detected signs of synovitis and bone edema in patients with early high active rheumatoid arthritis. The DFPP therapy enables a rapid and more complete suppression of inflammation in patients withearly high active rheumatoid arthritis. Nearly half of the patients (48.39%) who had received DFPP therapy achieved both clinical remission and imaging remission,a true remission. References Kirwan JR. Links between radiological change, disability, and pathology in rheumatoid arthritis.J Rheumatol 2001,28:881-886. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA. Progression of Radiologic Damage in Patients With Rheumatoid Arthritis in Clinical Remission. Arthritis Rheum 2004; 50:36-42. Brown AK, Conaghan PG, Karim Z, Quinn M A, Ikeda K, Peterfy CG, et al. An Explanation for the Apparent Dissociation Between Clinical Remission and Continued Structural Deterioration in Rheumatoid Arthritis. Arthritis & Rheumatism 2008,58: 2958-2967. Disclosure of Interest None Declared

Glucose-6-phosphate isomerase is associated with disease activity and declines in response to infliximab treatment in rheumatoid arthritis

Elevated Serum Glucose-6-Phosphate Isomerase Correlates with Histological Disease Activity and Clinical Improvement after Initiation of Therapy in Patients with Rheumatoid Arthritis

The Diagnostic Value of Glucose-6-phosphate Isomerase in Patients with Rheumatoid Arthritis

[Significance of glucose-6-phosphate isomerase assay in early diagnosis of rheumatoid arthritis]

Matrix metalloproteinase-3 and-9 : possible biomarkers of infliximab efficacy in ankylosing spondylitis ( AS ) ?

[Diagnostic Value of Glucose-6-phosphate Isomerase in Rheumatoid Arthritis Patients: Systematic Review].

Glucose-6-phosphate isomerase promotes the proliferation and inhibits the apoptosis in fibroblast-like synoviocytes in rheumatoid arthritis

THU0156 Response of Ra on MRI-detected Synovitis to Double Filtration Plasmapheresis

[Platelet Count Predicts Therapeutic Response of Infliximab for Active Crohn's Disease].

The Diagnostic Value of Gluocose-6-phosphate Isomerase in Patient with Rheumatoid Arthritis

Revisit of autoimmunity to glucose-6-phosphate isomerase in experimental and rheumatoid arthritis

The Role and Clinical Implications of G6PI in Juvenile Idiopathic Arthritis

Diagnostic Value of Rheumatoid Factor, Glucose-6-phosphate Isomerase and Anti-Cyclic Citrullinated Peptide Antibodies for the Patients with Rheumatoid Arthritis.

The Detection and Clinical Application of Glucose-6-phophate Isomerase-Containing Complex in Rheumatoid Arthritis

Regulatory T cells control the transition from acute into chronic inflammation in glucose-6-phosphate isomerase-induced arthritis

Pathogenic antibody response to glucose-6-phosphate isomerase targets a modified epitope uniquely exposed on joint cartilage

Therapeutic effects of antibodies to tumor necrosis factor-α, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis

Expression of Interleukin-18, Il-18bp, and Il-18r in Serum, Synovial Fluid, and Synovial Tissue in Patients with Rheumatoid Arthritis

Glucose-6-Phosphate Isomerase (G6PI) Mediates Hypoxia-Induced Angiogenesis in Rheumatoid Arthritis

Possible Role of Β-Galactosidase in Rheumatoid Arthritis

Good Response to Infliximab in Rheumatoid Arthritis Following Failure of Interleukin-1 Receptor Antagonist